Status:
COMPLETED
Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer
Lead Sponsor:
R-Pharm
Conditions:
Advanced Solid Tumors
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.
Eligibility Criteria
Inclusion
- Up to three prior chemotherapy regimens
- Measurable or non-measurable disease
- Available for treatment and follow-up
Exclusion
- Neuropathy
- Uncontrolled cardiovascular disease
- Refusal to participate in genetic analysis
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00207090
Start Date
September 1 2005
End Date
November 1 2008
Last Update
November 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195